17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest inhibiting STAT3 or immune checkpoint inhibitors could help treat idiopathic pulmonary fibrosis (IPF) or sarcoidosis-associated pulmonary fibrosis. In IPF patients, lung levels of PD-1...
18:16 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended discontinuing for futility the Phase III CREATE-1 trial of once-weekly oral AXS-02 (disodium zoledronate tetrahydrate) for six weeks to treat pain associated with complex regional pain syndrome...
12:51 , Jun 14, 2017 |  BC Innovations  |  Distillery Techniques

Imaging

TECHNOLOGY: PET A COL1 -targeting PET imaging agent could help detect pulmonary fibrosis and monitor treatment responses. The agent consisted of the 68 Ga PET radionuclide complexed with a COL1-targeting peptide that bound human and...
20:17 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

HT-100 regulatory update

FDA granted Akashi clearance to resume clinical development of Duchenne muscular dystrophy (DMD) candidate HT-100. The company said it plans to start a new Phase IIa trial “as quickly as possible.” In January 2016, Akashi...
22:31 , Mar 22, 2017 |  BC Extra  |  Clinical News

Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100 . The company said it intends to start a new Phase IIa trial “as...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS...
07:00 , Oct 13, 2016 |  BC Innovations  |  Product R&D

Elastic bones

A group at Northwestern University has created a "hyperelastic bone" scaffold to address the need for a bone-inducing material that is easily manufactured, low cost and easy to manipulate during surgery. While the short-term goal...
07:00 , Jun 30, 2016 |  BC Innovations  |  Translation in Brief

Keep quiescent and carry on

A major obstacle for stem cell therapies is their loss of regenerative potency as the cells are expanded or modified in vitro . A team from Stanford University has developed an artificial niche whose pharmacological...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: In vitro system to preserve muscle stem cell quiescence pre-transplant and regenerative potency post-transplant

Drug platforms TECHNOLOGY: Cell therapy An artificial in vitro niche could help preserve muscle stem cell quiescence before transplant to enhance regenerative potency after transplant. The niche consisted of engineered artificial muscle fibers composed of...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa halted

Akashi said that a patient treated with HT-100 in the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD has died. In late January, Akashi suspended dosing and...